Sort   by:  
 Page size 
TranscriptomicsRNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib
To investigate changes to gene expression associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10304 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human oesophageal adenocarcinoma OE19 cell line following PPARGC1A knock-down and 24 hour lapatinib treatment
To determine genes regulated by the transcriptional co-activator PPARGC1A in OAC cells and whether PPARGC1A activity is altered by lapatinib we performed RNA-seq on OE19 cells treated with non-targeting siRNA or siRNA targeting PPARGC1A. 24 hours post-transfection, cells were also treated with eithe...
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10317 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma WTSI-OESO_009 (CAM408) organoid treated with lapatinib
To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on WTSI-OESO_009 cells treated with 1000 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10306 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib for 35 days followed by drug withdrawal
To investigate whether changes to chromatin accessibility associated with resistance to lapatinib are a stable or a reversible state, we treated OE19 cells with 500 nM lapatinib for 35 days and then withdrew lapatinib for 1, 2, 3 and 14 days. Control cells treated with DMSO for 1 day and 'resistant'...
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10314 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human gastric adenocarcinoma NCI-N87 cell line treated with lapatinib
To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on NCI-N87 cells treated with 250nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10313 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib
To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10302 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma ESO26 cell line treated with lapatinib
To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on ESO26 cells treated with 500 nM lapatinib plus 1000 nM MK-2206 (an AKT inhibitor) for 24 hours and vehicle control (DMSO) for 24 hours.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10307 | biostudies-arrayexpress
GenomicsChIP-seq of HNF4A, PPARGC1A and H3K27ac in oesophageal adenocarcinoma OE19 cells treated with lapatinib
ChIP-seq for HNF4A, PPARGC1A and H3K27ac was performed in OE19 cells to identify genomic binding sites. Cells were treated with DMSO or 500 nM lapatinib for 48 hours.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10319 | biostudies-arrayexpress
UnknownActive symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
Not available
S-EPMC2431123 | biostudies-literature
UnknownSARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808 | biostudies-literature
Sort   by:  
 Page size